Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anacor’s Tavaborole May Lag Valeant’s Competing Antifungal In Both Efficacy And Approval Time

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Anacor released positive top-line Phase III data for the most advanced of its boron-based anti-infectives, the antifungal tavaborole, but the results weren’t good enough for some shareholders who were looking for the compound to best Valeant’s antifungal, currently pending at FDA with a May action date.


Related Content

GSK Ends Deal For Anacor’s Antibiotic, Returns Rights


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts